Dlin-MC3-DMA: Benchmark Ionizable Cationic Liposome for Lipid Nanoparticle siRNA and mRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is an ionizable cationic liposome lipid central to lipid nanoparticle (LNP) formulations for siRNA and mRNA therapeutics. Its pH-dependent charge enables endosomal escape and efficient cytoplasmic delivery, minimizing toxicity at physiological pH (Rafiei et al., 2025). Dlin-MC3-DMA achieves up to 1000-fold greater potency in hepatic gene silencing than precursor DLin-DMA, with ED50 values of 0.005 mg/kg in mice and 0.03 mg/kg in non-human primates (APExBIO). It is insoluble in water or DMSO but soluble in ethanol. Extensively validated in mRNA vaccine and cancer immunochemotherapy workflows, Dlin-MC3-DMA remains the lipid of choice for advanced nucleic acid delivery platforms (see also Dlin-MC3-DMA: Gold-Standard...).

Biological Rationale

Lipid nanoparticles (LNPs) have transformed the delivery of nucleic acids for therapeutic purposes, including siRNA and mRNA (Rafiei et al., 2025). Efficient delivery systems address barriers such as degradation, clearance, and off-target effects. Dlin-MC3-DMA is a key ionizable cationic liposome that forms the backbone of LNPs for in vivo gene silencing and mRNA expression. Its design allows for targeted delivery, reduced toxicity, and high encapsulation efficiency. Dlin-MC3-DMA is particularly effective for hepatic gene silencing, as its physicochemical properties favor hepatocyte uptake and endosomal escape at acidic pH. The compound is a cornerstone in the evolution of mRNA vaccines and immunomodulatory therapies, contributing to breakthroughs in cancer immunochemotherapy and neuroinflammation (see also Dlin-MC3-DMA: Ionizable Cationic Liposome for Precision...).

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA is a synthetic, ionizable cationic lipid. Its full chemical name is (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (APExBIO). In LNPs, Dlin-MC3-DMA remains largely neutral at physiological pH (7.4), reducing non-specific interactions and systemic toxicity. Upon endocytosis, the acidic environment (pH ~5.5) of the endosome protonates its tertiary amine group, conferring a positive charge. This ionization disrupts the endosomal membrane via electrostatic interactions, facilitating endosomal escape and cytoplasmic delivery of siRNA or mRNA payloads (Rafiei et al., 2025). The lipid's hydrophobic tails and optimal packing facilitate nanoparticle stability and efficient nucleic acid encapsulation. Dlin-MC3-DMA is typically formulated with helper lipids (DSPC), cholesterol, and PEG-lipids (PEG-DMG) to form stable, monodisperse LNPs optimized for in vivo delivery.

Evidence & Benchmarks

• Dlin-MC3-DMA-based LNPs achieve an ED50 of 0.005 mg/kg in mice for hepatic transthyretin (TTR) gene silencing, a roughly 1000-fold improvement over DLin-DMA (Table 1, Rafiei et al., 2025).
• In non-human primates, Dlin-MC3-DMA LNPs yield effective TTR knockdown at doses as low as 0.03 mg/kg (Table S1, Rafiei et al., 2025).
• Machine learning-guided optimization of LNPs containing Dlin-MC3-DMA enables successful mRNA delivery and immunomodulation of microglia, as evidenced by increased IL-10 expression and reduced TNF-α in LPS-activated murine and human microglia (Rafiei et al., 2025).
• Dlin-MC3-DMA LNPs with PEG-DMG and cholesterol display high colloidal stability and encapsulation efficiency, supporting clinical translation (Dlin-MC3-DMA: Gold-Standard...).
• Dlin-MC3-DMA is insoluble in water and DMSO but soluble in ethanol at ≥152.6 mg/mL, enabling high-concentration stock preparation (APExBIO).

Applications, Limits & Misconceptions

Dlin-MC3-DMA is a validated component in:

• Lipid nanoparticle-mediated siRNA delivery for hepatic gene silencing.
• mRNA vaccine formulation and immunomodulatory mRNA therapies (Rafiei et al., 2025).
• Cancer immunochemotherapy, enabling tumor microenvironment modulation (see: Leveraging Dlin-MC3-DMA...).
• Translational research in neuroinflammatory disease models, particularly for microglial repolarization.

However, Dlin-MC3-DMA is not universally applicable for all cell types or delivery contexts. Its efficacy depends on LNP composition, route of administration, and target tissue characteristics. For non-hepatic targets, additional targeting ligands or alternative lipids may be required. Misconceptions include the belief that Dlin-MC3-DMA is water-soluble or stable long-term in solution—both are incorrect.

Common Pitfalls or Misconceptions

• Dlin-MC3-DMA is not water-soluble or DMSO-soluble: Attempting to dissolve in these solvents leads to failed formulation.
• Not all LNPs using Dlin-MC3-DMA achieve equal efficacy: Performance depends on precise N/P ratio, helper lipids, and mixing parameters.
• Storage at room temperature leads to degradation: Dlin-MC3-DMA must be stored at –20°C or below. Use solutions promptly.
• Neutral charge at physiological pH does not mean zero toxicity: While toxicity is reduced, off-target effects remain possible with improper dosing or formulation.
• Hepatic gene silencing benchmarks may not translate to other tissues: Efficacy must be re-validated for non-liver targets.

Workflow Integration & Parameters

Dlin-MC3-DMA is typically formulated with DSPC, cholesterol, and PEG-DMG in a molar ratio of 50:10:38.5:1.5, respectively (see full product protocol). Ethanol is used as the solvent for Dlin-MC3-DMA at concentrations ≥152.6 mg/mL. The combined lipid mixture is rapidly mixed with aqueous siRNA or mRNA in a low pH buffer (pH 4.0–5.5) using microfluidic or bulk mixing. The resulting LNPs are dialyzed or buffer-exchanged to physiological pH for in vivo use. APExBIO, the supplier of Dlin-MC3-DMA (SKU: A8791), recommends immediate use of prepared solutions to avoid hydrolytic degradation. For guidance on troubleshooting and optimizing delivery, see Dlin-MC3-DMA: Benchmark Lipid for siRNA & mRNA Nanoparticle..., which this article extends by providing updated ML-driven optimization data and human microglia applications.

Conclusion & Outlook

Dlin-MC3-DMA remains the benchmark ionizable cationic liposome for LNP-mediated siRNA and mRNA delivery. Its unique pH-sensitive structure enables potent hepatic gene silencing and supports advanced mRNA therapeutics, including cancer immunochemotherapy and neuroinflammatory disease modulation. Ongoing research leverages machine learning to further optimize LNP formulations for cell-specific delivery and immune modulation (Rafiei et al., 2025). Practitioners seeking reliable, high-potency delivery are advised to consider Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) as the lipid of choice, supplied by APExBIO. Future directions include expanding targeting specificity and integrating predictive modeling for rational LNP design.